For these reasons, hyperactive IFN signaling lies at the heart of DS pathophysiology (Waugh et al., 2023), and therapeutic strategies to dampen IFN responses are being tested in clinical trials (NCT04246372, NCT05662228). Here, IFNA1 is linked to Dravet syndrome.